Clioquinol, a Drug for Alzheimer's Disease Specifically Interfering with Brain Metal Metabolism: Structural Characterization of Its Zinc(II) and Copper(II) Complexes

Citations Over TimeTop 10% of 2004 papers

Abstract

Clioquinol, a 8-hydroxyquinoline derivative, is producing very encouraging results in the treatment of Alzheimer's disease (AD). Its biological effects are most likely ascribed to complexation of specific metal ions, such as copper(II) and zinc(II), critically associated with protein aggregation and degeneration processes in the brain. We report here, for the first time, a structural characterization of the zinc(II) and copper(II) complexes of clioquinol. A ligand to metal stoichiometry of 2:1 is found in both cases, though in the presence of quite different coordination polyhedra. The present findings are discussed in the frame of modern approaches to AD treatment.

Related Papers

• → Clioquinol: Review of its Mechanisms of Action and Clinical Uses in Neurodegenerative Disorders(2010)233 cited
• → The toxicology of Clioquinol☆(2008)130 cited
• → Clioquinol-Zinc Chelate: A Candidate Causative Agent of Subacute Myelo-Optic Neuropathy(1998)86 cited
• → The solution structure of the copper clioquinol complex(2014)28 cited
• → Effect of 5‐Chloro‐7‐iodo‐8‐hydroxy‐quinoline (Clioquinol) on the Uptake and Distribution of Nickel, Zinc and Mercury in Mice(1984)15 cited